Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) insider Peter Rahmer sold 4,508 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $20.03, for a total transaction of $90,295.24. Following the sale, the insider directly owned 223,657 shares of the company’s stock, valued at $4,479,849.71. The trade was a 1.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Peter Rahmer also recently made the following trade(s):
- On Tuesday, July 28th, Peter Rahmer sold 748 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.61, for a total transaction of $13,920.28.
- On Tuesday, June 30th, Peter Rahmer sold 50,000 shares of Relay Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $954,500.00.
Relay Therapeutics Price Performance
RLAY traded down $0.65 on Friday, reaching $18.77. 2,762,681 shares of the company’s stock were exchanged, compared to its average volume of 3,169,067. The stock has a market cap of $4.11 billion, a PE ratio of -11.96 and a beta of 1.69. Relay Therapeutics, Inc. has a twelve month low of $3.52 and a twelve month high of $21.27. The stock’s fifty day moving average price is $19.21 and its 200-day moving average price is $14.71.
Institutional Trading of Relay Therapeutics
Several institutional investors have recently made changes to their positions in RLAY. Sanctuary Advisors LLC lifted its holdings in Relay Therapeutics by 1.1% in the first quarter. Sanctuary Advisors LLC now owns 143,816 shares of the company’s stock valued at $1,431,000 after acquiring an additional 1,588 shares during the last quarter. Abel Hall LLC increased its stake in Relay Therapeutics by 16.2% during the fourth quarter. Abel Hall LLC now owns 12,984 shares of the company’s stock worth $110,000 after acquiring an additional 1,809 shares during the last quarter. Allworth Financial LP purchased a new stake in Relay Therapeutics in the second quarter valued at $34,000. Cresset Asset Management LLC raised its position in Relay Therapeutics by 5.0% in the third quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock valued at $203,000 after purchasing an additional 1,848 shares during the period. Finally, Prelude Capital Management LLC lifted its stake in shares of Relay Therapeutics by 18.7% in the 3rd quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock valued at $103,000 after purchasing an additional 3,100 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.
Wall Street Analysts Forecast Growth
RLAY has been the subject of several recent research reports. UBS Group set a $26.00 price target on Relay Therapeutics in a report on Tuesday, May 19th. Citizens Jmp boosted their price objective on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research note on Monday, August 10th. HC Wainwright upped their target price on Relay Therapeutics from $28.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Citigroup reaffirmed a “market outperform” rating on shares of Relay Therapeutics in a research note on Monday, August 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Relay Therapeutics in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.92.
Read Our Latest Research Report on RLAY
About Relay Therapeutics
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Featured Stories
- Five stocks we like better than Relay Therapeutics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
